|Bid||8.05 x 4000|
|Ask||8.28 x 800|
|Day's Range||8.22 - 8.40|
|52 Week Range||8.01 - 11.90|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Kiromic BioPharma ("the Company") (NASDAQ: KRBP), a pre-clinical stage biotechnology company using its proprietary DIAMOND® artificial intelligence ("A.I.") platform to improve drug discovery and development with a therapeutic focus on immune-oncology, today announced its financial results for the third quarter ended September 30, 2020, and provided an update on its corporate developments.
(FHTX)Shares of (FHTX) rose as much as 27% in the biotech’s first day as a public company. Foghorn (ticker: FHTX), one of the few biotechs to go public this week, trades on the Nasdaq. Foghorn is the 14th biotech to go public this month.
Kiromic BioPharma, Inc. (the "Company"), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology, today announced the closing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $12.00 per share, for gross proceeds of $15,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.